Comparison of the Sensitivity of NAT Using Pooled Donor Samples for HBV and That of a Serologic HBsAg Assay
Overview
Affiliations
Background: Studies were conducted using samples from early and late-stage HBV-infected persons to determine the pool size at which PCR had better sensitivity than a sensitive HBsAg chemoluminescence immunoassay (CLIA-HBsAg).
Study Design And Methods: HBV seroconversion panels were tested for HBsAg by CLIA and for HBV DNA by nested PCR (95% hit rate: 100 copies/mL); PCR was carried out at various dilutions. HBV serologically positive samples that were detected from the simultaneous screening of 540,161 routine whole-blood donations using CLIA-HBsAg and agglutination assays were also characterized for additional markers of HBV infection.
Results: In 9 of 10 HBV seroconversion panels, PCR had better sensitivity than CLIA-HBsAg at dilutions of 1-in-25 or lower. Of 65 CLIA-only confirmed-positive donor samples (agglutination assay-negative), 8 represented early infection, 2 of which were PCR positive at a 1-in-50 dilution but negative at a 1-in-100 dilution. Only 2 of 47 samples from probable late-stage HBV infection that were positive on CLIA only were PCR positive with 0.1-mL sample volume and the S-region primer; the remaining 45 samples required a 1.0-mL sample input and C-region primer for increased PCR positivity. The remaining 10 CLIA-only confirmed-positive donor samples were from HBV vaccine recipients. None of the 12 CLIA- and HBsAg-negative donor samples that were strongly anti-HBc reactive could be detected by PCR at any dilution; all 12 were PCR positive when undiluted, but 4 required a 1.0-mL input volume for PCR positivity.
Conclusion: For the detection of samples representing early-stage HBV infection, PCR at dilutions of 1-in-25 or lower (equivalent to a pool of < or =25 members) had greater sensitivity than CLIA-HBsAg. In contrast, samples from late-stage HBV infection were detected by PCR only with undiluted samples (0.1-mL or 1.0-mL input volumes), regardless of CLIA-HBsAg reactivity. Therefore, although NAT using minipools of 25 donations or less may be effective for the detection of early-stage HBV infection, it may not be effective for the detection of persistent HBV infection.
Pandey P, Tiwari A, Dara R, Aggarwal G, Rawat G, Raina V Asian J Transfus Sci. 2015; 9(2):189-94.
PMID: 26420943 PMC: 4562144. DOI: 10.4103/0973-6247.154252.
Chatterjee K, Agarwal N, Coshic P, Borgohain M, Chakroborty S Asian J Transfus Sci. 2014; 8(1):26-8.
PMID: 24678169 PMC: 3943140. DOI: 10.4103/0973-6247.126684.
Yazdani Y, Roohi A, Khoshnoodi J, Shokri F Avicenna J Med Biotechnol. 2013; 2(4):207-14.
PMID: 23408744 PMC: 3558164.
Reducing the risk of hepatitis B virus transfusion-transmitted infection.
Niederhauser C J Blood Med. 2012; 2:91-102.
PMID: 22287868 PMC: 3262354. DOI: 10.2147/JBM.S12899.
Velati C, Fomiatti L, Baruffi L, Piccinini V, Prati D, Reina A Blood Transfus. 2011; 9(4):455-61.
PMID: 21839007 PMC: 3200416. DOI: 10.2450/2011.0014-11.